Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than the sector average, notes the analyst, who also argues ...

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $298.00. The company’s shares closed yesterday at $289.02.

Nov. 28-Dec. 1 _ ISPS Handa Australian Open (Ryggs Johnston) Dec. 5-8 _ Nedbank Golf Challenge (Johannes Veerman) Advertisement Article continues below this ad Dec. 12-15 _ Alfred Dunhill ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

I’m Brian Gordon, tech reporter for The News & Observer, and this is Open Source, a weekly newsletter on business, labor and technology in North Carolina. Amgen CEO Bob Bradway stood in Holly ...

Brian Gordon I’m Brian Gordon, tech reporter for The News & Observer, and this is Open Source, a weekly newsletter on business, labor and technology in North Carolina. Amgen CEO Bob Bradway ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Teahupoo produced by far his worst RPR in two years when beaten by Lossiemouth in the Hatton’s Grace last month and, despite what the market says, this division is wide open. The clue was in the name ...

After wresting control of the match again, Sinner closed out a ruthless, efficient performance with a 6-3, 7-6 (4), 6-3 victory over Zverev, the second seed, to win his second Australian Open title.